These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10049086)

  • 1. Doxorubicin-induced cardiomyopathy.
    Ginsburg AD
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049086
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin-induced cardiomyopathy.
    Singal PK; Iliskovic N
    N Engl J Med; 1998 Sep; 339(13):900-5. PubMed ID: 9744975
    [No Abstract]   [Full Text] [Related]  

  • 3. Doxorubicin-induced cardiomyopathy.
    Muggia FM; Speyer JL
    N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
    [No Abstract]   [Full Text] [Related]  

  • 4. Doxorubicin-induced cardiomyopathy.
    Lipshultz SE; Grenier MA; Colan SD
    N Engl J Med; 1999 Feb; 340(8):653-4; author reply 655. PubMed ID: 10049085
    [No Abstract]   [Full Text] [Related]  

  • 5. Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone?
    Daiber A; Gori T; Münzel T
    J Am Coll Cardiol; 2011 May; 57(21):2190-3. PubMed ID: 21596235
    [No Abstract]   [Full Text] [Related]  

  • 6. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
    Simsir SA; Lin SS; Blue LJ; Gockerman JP; Russell SD; Milano CA
    Ann Thorac Surg; 2005 Aug; 80(2):717-9. PubMed ID: 16039240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin cardiomyopathy.
    Chatterjee K; Zhang J; Honbo N; Karliner JS
    Cardiology; 2010; 115(2):155-62. PubMed ID: 20016174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery from anthracycline cardiomyopathy--how can it be explained?
    Christiansen S
    J Heart Lung Transplant; 2009 Jul; 28(7):751. PubMed ID: 19560709
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug-induced myocarditis and cardiomyopathy].
    Takemoto Y; Yoshiyama M
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():589-92. PubMed ID: 23156578
    [No Abstract]   [Full Text] [Related]  

  • 10. Doxorubicin-induced myocardial injury.
    Fujisaki G; Inokuchi C; Murashige N
    N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
    [No Abstract]   [Full Text] [Related]  

  • 11. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression.
    Kuramochi Y; Takagi H; Morita T
    Eur Heart J; 2006 Nov; 27(21):2610-1; author reply 2611. PubMed ID: 17018546
    [No Abstract]   [Full Text] [Related]  

  • 12. [Myocardial toxicity by doxorubicin].
    Yu PC; Calderaro D; Ikeoka DT; Demarchi LM; Caramelli B
    Rev Assoc Med Bras (1992); 2005; 51(3):131. PubMed ID: 16007295
    [No Abstract]   [Full Text] [Related]  

  • 13. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
    Jin Z; Zhang J; Zhi H; Hong B; Zhang S; Guo H; Li L
    J Cardiol; 2013 Aug; 62(2):110-6. PubMed ID: 23731918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroid cardiomyopathy in a patient post-doxorubicin chemotherapy.
    Silver AJ; Patel HN; Okwuosa T
    BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27053539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular late effects.
    Camp-Sorrell D
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):42-4. PubMed ID: 18431900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.
    Octavia Y; Tocchetti CG; Gabrielson KL; Janssens S; Crijns HJ; Moens AL
    J Mol Cell Cardiol; 2012 Jun; 52(6):1213-25. PubMed ID: 22465037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenylamine inhibition of adriamycin-induced cardiomyopathy in mice.
    Milei J; Bolomo NJ; Marantz A
    Medicina (B Aires); 1982; 42(4):409-14. PubMed ID: 15171023
    [No Abstract]   [Full Text] [Related]  

  • 18. Epo 'cytokine-doping' of heart disease patients, will it work?
    Jørgensen E; Bindslev L; Ripa RS; Kastrup J
    Eur Heart J; 2006 Aug; 27(15):1767-8. PubMed ID: 16818456
    [No Abstract]   [Full Text] [Related]  

  • 19. Troponins for predicting cardiotoxicity from cancer therapy.
    Sparano JA; Wolff AC; Brown D
    Lancet; 2000 Dec; 356(9246):1947-8. PubMed ID: 11130520
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.
    Karagoz B; Suleymanoglu S; Uzun G; Bilgi O; Aydinoz S; Haholu A; Turken O; Onem Y; Kandemir EG
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):287-92. PubMed ID: 18248515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.